---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-24-000053"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2024-08-19T23:59:59+00:00"
generated_at: "2026-05-31T08:38:59.517519+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Supernus announces FDA accepted resubmission of SPN-830 NDA; PDUFA date Feb 1, 2025

## Summary
- FDA acknowledged resubmission of NDA for SPN-830 (apomorphine infusion device) for continuous treatment of motor fluctuations in Parkinson's disease.
- Resubmission is considered filed; user fee goal date (PDUFA) set for February 1, 2025.
- SPN-830 targets OFF episodes in Parkinson's disease; Supernus focuses on CNS therapies.

## SEC filing metadata
- accession: 0001356576-24-000053
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2024-08-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000053/0001356576-24-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000053/supn-20240819.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-24-000053
- JSON: https://secwatch.observer/filing/0001356576-24-000053.json
- Plain text: https://secwatch.observer/filing/0001356576-24-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.